ERBB2 and ovarian cancer: Although Her2/neu is a self-antigen, antibody and cytotoxic T lymphocyte (CTL) -specific responses against Her2/neu have been detected in some patients with Her2/neu overexpression in breast and ovarian cancers [6, 7];thus, immunological tolerance to Her2 is not absolute and can be overcome [5].